Tyche Industries Ltd

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift markedly, moving from an expensive to a very expensive rating. Despite a recent downgrade to a Strong Sell rating by MarketsMOJO, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios reveal a complex picture of price attractiveness relative to peers and historical benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions and impacts the stock's price attractiveness relative to its historical averages and peer group, amid a challenging industry backdrop and mixed financial performance.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 06 April 2026, providing investors with the latest insights into its performance and outlook.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.99.2 on 30 March 2026, marking a significant milestone in its ongoing price decline. The stock’s performance continues to reflect persistent downward pressure amid broader market weakness and company-specific financial trends.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters deteriorate sharply, with its price-to-earnings (P/E) ratio and price-to-book value (P/BV) signalling a shift from expensive to very expensive territory. This re-rating comes amid subdued financial performance and a challenging sector backdrop, raising concerns about the stock’s price attractiveness relative to peers and historical benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change accompanies a downgrade in its Mojo Grade to Strong Sell, reflecting growing concerns over its price attractiveness relative to historical and peer benchmarks.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions and impacts the stock's price attractiveness amid a challenging industry backdrop and mixed financial metrics.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade to Strong Sell. With its price-to-earnings (P/E) ratio easing from very expensive to merely expensive, alongside a subdued return profile compared to the Sensex, investors are urged to reassess the stock’s price attractiveness amid evolving market dynamics.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from fair to very expensive territory. This change, coupled with a recent downgrade to a Strong Sell rating, highlights growing concerns about the stock’s price attractiveness relative to its historical and peer benchmarks.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its recent quarterly financial performance, with key metrics signalling a very negative trend. The company’s latest quarter ending December 2025 saw revenue and profitability contract sharply, intensifying concerns among investors and analysts alike.

Tyche Industries Limited, a Hyderabad-based pharmaceutical manufacturer specialising in Glucosamine Hydrochloride and bulk drug intermediates, reported deeply concerning Q3 FY26 results that underscore accelerating operational deterioration. The company posted net profit of ₹1.82 crores for the quarter ended December 2025, marking a sharp decline of 19.78% quarter-on-quarter and a devastating 61.60% year-on-year contraction. With a market capitalisation of ₹121.00 crores, the micro-cap pharmaceutical player now faces mounting questions about its ability to reverse a multi-quarter downtrend that has seen both revenue and profitability collapse.